Accordingly, this study highlights the need for improved therapy for patients with PNH and future research should assess the real-world treatment patterns and hematologic responses of alternative therapies, such as C3-inhibition treatments. This evidence concerns the gene C3 and paroxysmal nocturnal hemoglobinuria.